Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

(2015) Urban Emmenegger et al.   NEOPLASIA

Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment

(2012) Kosuke Akiyama et al.   AMERICAN JOURNAL OF PATHOLOGY

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis

(2012) Hai-Long Zhang et al.   LUNG CANCER

Class III  -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial

(2011) A. C. Vilmar et al.   CLINICAL CANCER RESEARCH

Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?

(2011) Nicolas André et al.   Future Oncology

ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux

(2011) Michelle J. Henderson et al.   JNCI-Journal of the National Cancer Institute

Identification of class III β-tubulin as a marker of angiogenic perivascular cells

(2011) Peter C. Stapor et al.   MICROVASCULAR RESEARCH

Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer

(2011) R. De Souza et al.   MOLECULAR CANCER THERAPEUTICS

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors

(2011) Andreas Peyrl et al.   PEDIATRIC BLOOD & CANCER

Specific β-Tubulin Isotypes Can Functionally Enhance or Diminish Epothilone B Sensitivity in Non-Small Cell Lung Cancer Cells

(2011) Pei Pei Gan et al.   PLoS One

βIII-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non–Small Cell Lung Cancer

(2010) Joshua A. McCarroll et al.   CANCER RESEARCH

Multiple Drug Resistance Mechanisms in Cancer

(2010) Bruce C. Baguley   MOLECULAR BIOTECHNOLOGY

Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer

(2010) R. De Souza et al.   MOLECULAR CANCER THERAPEUTICS

ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties

(2010) E. Pasquier et al.   MOLECULAR CANCER THERAPEUTICS

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology

Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3

(2009) M. Michaelis et al.   CANCER RESEARCH

Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells

(2009) Y.-Q. Xiong et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response

(2009) Nan Soon Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioma-associated endothelial cells are chemoresistant to temozolomide

(2009) Jenilyn J. Virrey et al.   JOURNAL OF NEURO-ONCOLOGY

Tubulin proteomics: Towards breaking the code

(2008) Pascal Verdier-Pinard et al.   ANALYTICAL BIOCHEMISTRY

Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb  -Tubulin in Vinca Alkaloid Sensitivity

(2008) P. P. Gan et al.   CANCER RESEARCH

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

(2008) Pascal Sève et al.   LANCET ONCOLOGY

Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer

(2008) V. Vassileva et al.   MOLECULAR CANCER THERAPEUTICS